rss Posted June 17, 2010 Report Share Posted June 17, 2010 Related ArticlesAcne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient. J Oncol Pharm Pract. 2010 Jun 15; Authors: Demirci U, Coskun U, Erdem O, Ozturk B, Yilmaz IB, Benekli M, Buyukberber S Tyrosine kinase inhibitors (TKIs) are targeted treatments for various cancers. Skin toxicities are one of the most common nonhematological side-effects of TKIs. We report an imatinib mesylate (IM) induced hyperpigmented acne rosacea (AR) and sunitinib-induced palmar hyperkeratosis in the case with gastrointestinal stromal tumor. AR was arisen due to the discontinuation of IM. To the best of our knowledge, this kind of cutaneous side-effect with IM has not been documented previously. PMID: 20551113 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=20551113&dopt=Abstract = URL to article Link to comment Share on other sites More sharing options...
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!Register a new account
Already have an account? Sign in here.Sign In Now